Year None20212020201920182017 Nov 22, 2021 Tenaya Therapeutics Announces the Addition of Dr. June Lee to its Board of Directors Nov 19, 2021 Tenaya Therapeutics to Participate in Upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference Nov 10, 2021 Tenaya Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates Oct 12, 2021 Tenaya Therapeutics to Present Preclinical Data on Its Gene Therapy Programs at the ESGCT 28th Annual Congress Sep 30, 2021 Tenaya Therapeutics to Participate in Upcoming Investor and Industry Conferences Sep 08, 2021 Tenaya Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates Aug 31, 2021 Tenaya Therapeutics to Present at Morgan Stanley 19th Annual Global Healthcare Conference Aug 03, 2021 Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares Jul 29, 2021 Tenaya Therapeutics Announces Pricing of Upsized Initial Public Offering Jul 13, 2021 Tenaya Therapeutics Unveils Preclinical Research Supporting Product Candidate for Rare and Prevalent Heart Disease Indications at ESC Heart Failure 2021 Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 13
Nov 19, 2021 Tenaya Therapeutics to Participate in Upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference
Nov 10, 2021 Tenaya Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
Oct 12, 2021 Tenaya Therapeutics to Present Preclinical Data on Its Gene Therapy Programs at the ESGCT 28th Annual Congress
Sep 08, 2021 Tenaya Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
Aug 31, 2021 Tenaya Therapeutics to Present at Morgan Stanley 19th Annual Global Healthcare Conference
Aug 03, 2021 Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Jul 13, 2021 Tenaya Therapeutics Unveils Preclinical Research Supporting Product Candidate for Rare and Prevalent Heart Disease Indications at ESC Heart Failure 2021
